Integra launches Allograft Cancellous Sponge
This article was originally published in Clinica
Executive Summary
Integra LifeSciences has launched its Integra Allograft Cancellous Sponge, a compressible bone graft composed of 100% cancellous bone, in the US. The graft is used to replace damaged bone that has been surgically removed from the spine, extremities and pelvis, because of trauma, for example. Bone grafts such as Integra's provide a scaffold for the growth of new bone. The device can absorb fluids like saline, blood or bone marrow aspirate, and can conform to a variety of spaces and defects allowing surgical flexibility. The Integra distributor network will sell the sponge in the US. The US market size for bone graft substitutes in orthopaedic spinal procedures is estimated at $560m, excluding growth factors, stem cell therapies, and machined bone, the Plainsboro, New Jersey firm says.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?